Physician profile
Andrew A Hendricks
NPI 1740246115
$13,074.98
in general payments reported to CMS, 2019-2025
34 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,621 · 2020: $1,069 · 2021: $1,865 · 2022: $2,251 · 2023: $2,600 · 2024: $1,253 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,125 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,124.96 |
| Education | $145.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,084.26 | 2019-2025 | |
| Janssen Biotech, INC. | $1,523.44 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,350.38 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $835.82 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $817.92 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $469.04 | 2019-2024 | |
| Pfizer INC. | $427.36 | 2019-2025 | |
| Genzyme Corporation | $387.90 | 2019-2025 | |
| Merz North America, INC. | $375.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.70 | 2022-2025 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $306.15 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $294.13 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $247.66 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $200.37 | 2025 | Affinity, Via Matrix, Apligraf |
| Galderma Laboratories, L.P. | $194.08 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $175.01 | 2019-2022 | |
| Celgene Corporation | $135.28 | 2019 | |
| Organon LLC | $131.59 | 2025 | Vtama |
| Prugen, INC. Pharmaceuticals | $109.01 | 2019 | |
| Incyte Corporation | $92.36 | 2022-2024 | Opzelura |
| Ucb, INC. | $75.32 | 2021-2025 | Bimzelx |
| Biofrontera INC. | $69.16 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $66.99 | 2022 | |
| Arcutis Biotherapeutics, INC. | $60.46 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $58.14 | 2019-2023 | Xolair |
| Janssen Scientific Affairs, LLC | $51.40 | 2023 | Tremfya |
| Dermira, INC. | $48.49 | 2019 | |
| Novo Nordisk INC | $37.67 | 2021 | |
| Dusa Pharmaceuticals, INC. | $34.08 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $26.83 | 2021 | |
| Verrica Pharmaceuticals INC. | $19.35 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $19.00 | 2020 | |
| Botanix Sb INC | $16.63 | 2025 | Sofdra |
| Sebela Pharmaceuticals INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.